View ValuationNascent Biotech 将来の成長Future 基準チェック /06現在、 Nascent Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.お知らせ • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.お知らせ • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0お知らせ • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.お知らせ • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.お知らせ • Jan 11Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.お知らせ • Dec 21Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.お知らせ • Oct 06Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.お知らせ • Sep 14Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.お知らせ • Jun 30Nascent Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 24Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020.お知らせ • Aug 25Nascent Biotech, Inc. announced that it has received $0.74 million in fundingNascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Nascent Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NBIO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2024N/A-2-1-1N/A3/31/2024N/A-2-1-1N/A12/31/2023N/A-2-1-1N/A9/30/2023N/A-3-2-2N/A6/30/2023N/A-2-2-2N/A3/31/2023N/A-3-2-2N/A12/31/2022N/A-3-1-1N/A9/30/20221-1-1-1N/A6/30/20221-100N/A3/31/20221000N/A12/31/20212000N/A9/30/20211-100N/A6/30/20211-100N/A3/31/20211-1-1-1N/A12/31/2020N/A-4-1-1N/A9/30/2020N/A-4-1-1N/A6/30/2020N/A-400N/A3/31/2020N/A-4-1-1N/A12/31/2019N/A-100N/A9/30/2019N/A-1-1-1N/A6/30/2019N/A-1-1-1N/A3/31/2019N/A-1-1-1N/A12/31/2018N/A-2-1-1N/A9/30/2018N/A-2-1-1N/A6/30/2018N/A-2-1-1N/A3/31/2018N/A-2N/A-1N/A12/31/2017N/A-2N/A-1N/A9/30/2017N/A-2N/A-1N/A6/30/201720N/A0N/A3/31/201731N/A-1N/A12/31/201631N/A0N/A9/30/201631N/A0N/A6/30/20161-3N/A0N/A3/31/2016N/A-4N/A0N/A12/31/2015N/A-4N/A0N/A9/30/2015N/A-5N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NBIOの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NBIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NBIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NBIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NBIOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NBIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:24終値2026/05/21 00:00収益2024/06/30年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nascent Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.
お知らせ • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.
お知らせ • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0
お知らせ • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.
お知らせ • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
お知らせ • Jan 11Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
お知らせ • Dec 21Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.
お知らせ • Oct 06Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.
お知らせ • Sep 14Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
お知らせ • Jun 30Nascent Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 24Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020.
お知らせ • Aug 25Nascent Biotech, Inc. announced that it has received $0.74 million in fundingNascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors.